Go directly to your valve problem
Mitral valve repair or replacement: what matters?
For severe degenerative mitral regurgitation requiring intervention, repair is preferred when a durable reconstruction is feasible. Preserving the native valve avoids a replacement prosthesis, but the chance of repair depends on the specific lesion.
Secondary regurgitation caused by heart-muscle or chamber changes follows a different pathway. Optimized heart-failure treatment and selected catheter interventions may be relevant.
Sources: ESC/EACTS valve guidance (2025) · UK Mini Mitral trial · JAMA (2023) · Mitral and Tricuspid Valve Center | Cleveland Clinic
Mechanical or tissue heart valve: key trade-offs
Mechanical valves offer durability at the cost of lifelong anticoagulation. Tissue valves can deteriorate and may need another intervention. Other conditions can require blood thinners even with a tissue valve.
| Option | Potential advantage | Long-term trade-off |
|---|
| Mechanical valve | Long durability | Lifelong anticoagulation and bleeding/monitoring burden |
|---|
| Tissue valve | No lifelong anticoagulation requirement solely because the valve is mechanical | Structural deterioration and possible reintervention; medicines may still be needed for other reasons |
|---|
| Repair | Retains the native valve | Feasibility and durability depend on the lesion and reconstruction |
|---|
Sources: NHS: valve types · ESC/EACTS valve guidance (2025)
TAVI or surgical aortic valve replacement?
TAVI places a replacement aortic valve using a catheter. Surgical aortic valve replacement removes and replaces the valve during an operation. The choice includes the valve and access anatomy, other disease, life expectancy, preferences and the likelihood of future procedures.
For severe aortic stenosis requiring intervention, the 2025 ESC/EACTS guidance supports TAVI in anatomically suitable patients aged 70 or older with a three-leaflet (tricuspid) aortic valve. That is not a universal age rule: bicuspid valves, younger patients and the need for other surgery can change the decision.
- Three-leaflet versus bicuspid anatomy affects suitability.
- Concomitant coronary, aortic or other valve disease may favour a combined operation.
- Valve size and coronary access influence future treatment options.
Sources: ESC/EACTS valve guidance (2025)
What is TEER, and when is it considered?
TEER reduces leakage by bringing parts of a valve together with a catheter-delivered device. It is different from surgical repair and from TAVI.
For selected symptomatic severe ventricular secondary mitral regurgitation despite optimized heart-failure treatment, the 2025 European guideline supports TEER to reduce heart-failure admissions and improve quality of life.
Sources: ESC/EACTS valve guidance (2025) · Bumrungrad Heart Valve Center
Minimally invasive and robotic valve surgery
A mitral repair may be possible through sternotomy, a smaller chest incision or a robot-assisted approach. Choose the repair plan and experienced team together with the access route. The same technique label does not make different valve procedures directly comparable.
Sources: UK Mini Mitral trial · JAMA (2023) · Mayo Clinic: minimally invasive surgery
Recovery and follow-up after valve treatment
Valve follow-up includes medication and anticoagulation management where indicated, imaging, rehabilitation and wound review. NHS guidance describes about a week in hospital and two to three months to full recovery after chest-incision valve replacement, with a shorter initial stay after TAVI.
Sources: NHS: valve recovery
Specialists for this treatment pathway
Explore each specialist’s clinical focus, current programme and the studies relevant to this treatment. The listed roles include cardiac surgeons and, where appropriate, interventional cardiologists.
Continue your guide
Related heart surgery guides